We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
21 Jun 2021 - 24 Jun 2021

African-American MS Patients Experience More Rapid B-Cell Repopulation

By LabMedica International staff writers
Posted on 06 May 2021
Print article
Image: Histology showing pathological and immunopathological findings from a spinal cord lesion from a 52-year-old woman who died from active neuromyelitis optica associated with a longitudinally extensive spinal cord lesion extending from C3 to T8 (Photo courtesy of CHU de Strasbourg)
Image: Histology showing pathological and immunopathological findings from a spinal cord lesion from a 52-year-old woman who died from active neuromyelitis optica associated with a longitudinally extensive spinal cord lesion extending from C3 to T8 (Photo courtesy of CHU de Strasbourg)
Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between the brain and the rest of the body.

Neuromyelitis optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis). Classically, it was felt to be a monophasic illness, but the interval between attacks may be weeks, months or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS).

Medical Scientists from the NYU Grossman School of Medicine (New York, NY, USA) enrolled in a retrospective cross-sectional study, 168 patients, including 61 African-American patients, 60 white patients, and 47 who identified as other races; about 19% were Hispanic. About 80% of the patients were diagnosed with multiple sclerosis, and 19% had neuromyelitis optica spectrum disorder. The team also looked at the types of B cells being repopulated and found there were no differences between African-Americans and whites in the makeup of the cells.

The team reported that in the 6 to 12 months after undergoing treatment with rituximab or ocrelizumab to deplete B cells, African-Americans patients were more than twice as likely to have B cell repopulation compared with white patients (76% versus 33%). In the four to six months following treatment, however, repopulation of B cells was about the same in both groups, at roughly 21% in the African-American patients compared with 18% in the white patients. No patients had B cell repopulation within four months of treatment. At four to six months, 23% had B cell repopulation and by after 10 months, 90% had repopulation of their B cells.

Lucia Saidenberg, MD, an author of the study, said, “Anti-CD20 therapy, including rituximab and ocrelizumab, are highly effective treatments for multiple sclerosis and neuromyelitis optica spectrum disorder and are known to cause a near complete depletion of B cells in the blood soon after infusion. However, repopulation of B cells following anti-CD20 infusion has not been well studied in these patients, particularly not in African-American patients, who are underrepresented in clinical trials for these drugs and tend to have more severe disease and faster disease progression compared to white patients with multiple sclerosis.” The study was presented at the American Academy of Neurology virtual meeting held April 17-22, 2021.

Related Links:
NYU Grossman School of Medicine

New
Gold Supplier
SARS-CoV2 Antigen Rapid Test
SARS-CoV2 Antigen Rapid Test
New
Silver Supplier
NGS Prep System (RUO)
Magnis NGS Prep System (RUO)
New
COVID-19 Detection Kits
PCR Diagnostic Solution
New
D-Dimer ELISA Kit
D-Dimer AccuBind ELISA Kit

Print article
BIOHIT  Healthcare OY

Channels

Clinical Chem.

view channel
Image: Blood test for  plasma aldosterone concentration was used to screen For hyperaldosteronism in hypertensive men (Photo courtesy of  VisitHealth Ltd)

Urinary Sodium/Potassium Ratio Screens for Hyperaldosteronism in Hypertensive Men

Among individuals with hypertension, the prevalence of secondary hypertension has been reported to be around 10%. More than half of individuals with secondary hypertension have associated hyperaldosteronism.... Read more

Industry

view channel
Illustration

Global Clinical Chemistry Analyzers Market to Reach USD 15.97 Billion by 2028

The global clinical chemistry analyzers market is projected to grow at a CAGR of 4.25% from USD 11.45 billion in 2020 to USD 15.97 billion by 2028, driven by growth in technology, rising global population,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.